Copenhagen, Denmark; December 11, 2012 – Genmab A/S (OMX: GEN) announced today it has reached a key milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. and its affiliates (“Janssen”), triggering a $ 2 million payment. The milestone is for achieving technical proof-of-concept for the first DuoBody product candidate.
